Pharmaceuticals, Biotechnology & Life Sciences

Insider STOVER JACK E buys Traws Pharma options, signaling confidence in the company’s pivot to antiviral therapeutics and potential future upside.

Oncolytics Biotech insider trades reveal CEO Oyler John’s disciplined 10b‑5‑1 strategy—selling high, buying low—while key clinical milestones loom.

Insider buying of Traws Pharma options shows executive confidence in its new respiratory‑therapeutics push—watch FDA milestones for upside.

Discover how Longeveron’s insider buying and selling signals investor confidence amid a 57% stock drop and promising Phase 2a results.

Explore how CEO David Kirn’s 10(b)(5) sales affect 4D Molecular Therapeutics’ share price, market sentiment, and future confidence.

United Therapeutics insider buys and sells reveal CEO Martine Rothblatt’s disciplined 10(b)(5)(1) plan—signaling confidence, minimal dilution, and future stock‑sale timing.

Armata CEO sells 14,041 shares to cover tax obligations amid a 66% yearly slump, yet FDA pediatric study plans signal long‑term growth prospects.

CEO insider buys at Elanco signal confidence: 2M+ shares acquired at near market price, high social buzz, and potential near‑term rally for investors.

CG Oncology insider James Mulay buys shares at one‑third the market price yet sells at a premium—insight into his confident, disciplined trading strategy and the company’s upside potential.

Insider selling at ANI: Cook Meredith’s structured 500‑share July sale shows routine trading, not panic—monitor Phase‑4 ILUVIEN results for future upside.